Healthcare

The primary verified catalyst anchoring current analysis for Invion Ltd. is Why Invion (ASX: IVX) Photosensitiser Chemistry Accelerates Tissue-Sparing Cancer Ablation. Operationally, management has directed executive focus and capital resources toward progressing pre-clinical and early clinical trial protocols in accessible non-melanoma skin and solid …

The primary verified catalyst anchoring current analysis for Orthocell Ltd is What Orthocell (ASX: OCC) Global Collagen Approvals Mean for Nerve and Tendon Reconstruction. Operationally, management has directed executive focus and capital resources toward expanding commercial distribution networks for CelGro and Remplir across the …

The primary verified catalyst anchoring current analysis for Argent Biopharma Ltd is Why Argent Biopharma (ASX: RGT) Neurological Drug Repurposing Strategy Broadens Clinical Access. Operationally, management has directed executive focus and capital resources toward advancing clinical-grade cannabinoid-derived prescription medicines targeting refractory epilepsy and pain. …

In an increasingly complex macroeconomic climate shaped by volatile interest rate expectations and shifting global growth dynamics,Exchange-traded fundsoffer unmatched liquidity, transparency, and administrative simplicity. For self-managedSuperannuationfunds and privateWealthbuilders alike, IXJ functions as a core portfolio building block designed to deliver targeted asset-class participation while …

For the year ended 31 March 2026, Fisher & Paykel Healthcare (ASX:FPH) reported operating revenue of NZD 2.31 billion, a 14% year-on-year increase, or 12% in constant currency. Net profit after tax reached NZD 468.5 million, up 24% year on year, or 28% in …

Sonic Healthcare (ASX:SHL) reported FY2026 revenue of approximately AUD 10.9 billion, an increase of 13% year on year. Underlying EBITDA was AUD 1.93 billion, up 11%, and underlying net profit reached AUD 621 million, up 17%. UnderlyingEarnings Per Shareincreased 14% to 125.6 Australian cents. …

For the financial year ended 30 June 2026, CSL (ASX:CSL) reported total revenue of USD 15.797 billion. Underlying net profit after tax andAmortisationattributable to ordinary shareholders was USD 3.098 billion, down 2% on a constant-currency basis. The company reported a statutory net loss of …